Stroke clinical trial update & notice of results

RNS Number : 7372R

ReNeuron Group plc

09 November 2011

 



                            

     

      PRESS RELEASE

Update on stroke clinical trial

Notification of date of interim results: Monday 28 November 2011

Guildford, UK, 9 November 2011: ReNeuron Group plc (LSE: RENE.L) ("ReNeuron" or "the Company") today provides an update on progress with the PISCES Phase I clinical trial of its ReN001 stem cell therapy for disabled stroke patients, and confirms the date for its forthcoming 2011 interim results statement, being Monday 28 November 2011. 

ReNeuron recently announced that the first patient in the second dose cohort of the PISCES study had been successfully treated with ReN001.  In line with the clinical trial protocol, the independent Data Safety Monitoring Board (DSMB) for the clinical trial has reviewed the status of this patient at 28 days post-treatment.  The Company is pleased to report that, based on this review, the DSMB has determined that the study can progress to treatment of the remainder of the second dose cohort of three patients.  The next patient in this cohort is scheduled to be treated this month.

The Company is also pleased to report that the first patient dosed in the PISCES clinical trial has now attended his 12 month follow-up visit and remains well, with no cell-related adverse events reported.

ReNeuron expects that all remaining patients in the PISCES clinical trial will be treated in 2012.  Based on progress with the study thus far, the Company has commenced interactions with the UK regulatory authorities regarding further amendments to the PISCES clinical trial protocol, in order that the ReN001 therapy can progress towards proof-of-concept efficacy studies in the earliest possible timeframe assuming continued favourable readouts from the PISCES study. 

ReNeuron will provide a further update on the PISCES clinical trial in its 2011 interim results statement to be announced on Monday 28 November 2011.  A briefing for analysts will be held at 10:00am (BST) on the day at the offices of Buchanan Communications, 107 Cheapside, London EC2V 5DN.

In addition, Professor Keith Muir, the Principal Investigator for the study, will present further data regarding progress with the PISCES clinical trial at the Stroke Association's 6^th UK Stroke Forum Conference in Glasgow from 29 November to 1 December 2011.

The PISCES study (Pilot Investigation of Stem Cells in Stroke) is the world's first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients.  Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world.  The trial is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board. 

Michael Hunt, Chief Executive Officer of ReNeuron, said:

"The 12 month follow-up visit of the first patient treated is an important milestone in the PISCES study and we are delighted that he remains well and that no cell-related adverse events have arisen.  We look forward to providing further updates on the clinical trial in our 2011 interim results statement, and at the UK Stroke Forum meeting that follows it."

Enquiries:

Michael Hunt, Chief Executive Officer - ReNeuron              [phone]

Dr John Sinden, Chief Scientific Officer - ReNeuron

Lisa Baderoon, Mark Court, Isabel Podda                        [phone]

Buchanan Communications                                      

Antony Legge, Oliver Rigby                                                  [phone]

Daniel Stewart & Company plc                              

Ross Barker, Media Relations Officer                                 [phone]

University of Glasgow

About stroke

Approximately 150,000 people suffer a stroke in the UK each year.  The vast majority of these strokes are ischaemic in nature, caused by a blockage of blood flow in the brain (as opposed to a haemorrhagic or bleeding stroke). 

Approximately one half of all stroke survivors are left with permanent disabilities as a result of the damage caused to brain tissue arising from the stroke.  The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK, with stroke patients estimated to be occupying at least 25 per cent of long term hospital beds.

The only current treatment for ischaemic stroke patients occurs in the acute phase of the condition (within several hours of the stroke), when anti-clotting agents are administered to dissolve the clot causing the blockage in blood flow to the brain.  Only a small proportion of patients get to the hospital in time to be treated in this way.

Beyond the acute phase, there are no existing treatments, other than preventative or rehabilitation measures, to alleviate the disabilities suffered by stroke patients who have survived their stroke.

Source: UK Stroke Association

About ReNeuron's ReN001 stem cell therapy for stroke

ReNeuron's ReN001 cell therapy for stroke consists of a neural stem cell line, designated CTX, which has been generated using the Company's proprietary cell expansion and cell selection technologies and then taken through a full manufacturing scale-up and quality-testing process.  As such, ReN001 is a standardised, clinical and commercial-grade cell therapy product capable of treating all eligible patients presenting. 

ReN001 has been shown to reverse the functional deficits associated with stroke disability when administered several weeks after the stroke event in relevant pre-clinical models of the condition.   Extensive pre-clinical testing also indicates that the therapy is safe, with the ReN001 cells eventually cleared from the body with no adverse safety effects arising. 

If ultimately shown to be safe and effective clinically, ReN001 would therefore offer a significant new treatment option for stroke survivors.  The therapy offers the potential for a degree of recovery of function in disabled stroke patients, resulting in greater independence and quality of life for these patients and reduced reliance on health and social care systems.

The ReN001 cells that are being used in the initial clinical trial are taken from the existing manufactured cell banks that will form the basis of the eventual marketed product.  There will therefore be no need to re-derive and test new ReN001 cell lines for subsequent clinical trials or for the market - all such cells can simply be expanded from the existing banked and tested product.

About the Institute of Neurological Sciences at the University of Glasgow

The clinical Stroke Research Group of the Division of Clinical Neurosciences is based at the Institute of Neurological Sciences at the University of Glasgow and has major collaborations, internally with the Glasgow Experimental MRI Centre, with SINAPSE (Scottish Imaging Network: A Platform for Scientific Excellence), and with the Translational Medicine Research Initiative (TMRI).  Around 900 patients per year are admitted through the Acute Stroke Unit, which provides stroke services to the population of south Glasgow and specialist stroke treatments for the West of Scotland.

The unit is the highest user of acute clot-busting (thrombolytic) treatment in the UK at present, and has been extensively involved in clinical trials in stroke.   Major research interests include evaluation of advanced brain imaging techniques in acute stroke, development of novel brain imaging techniques, improving the use of clot-busting drug treatments in stroke, and developing trial methodology for evaluation of regenerative treatments. The group has support from the Stroke Association, the Medical Research Council, and the TMRI.  Further work with regenerative strategies include collaborations with groups developing both drug-based and stem cell therapies across Europe.

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell^®products for use in academic and commercial research.  The Company's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

END

 

 

MSCBIBDBLUGBGBI